22nd Biennial Course in Urologic Oncology

Registration

Welcome
Anthony D'Amico, MD, PhD

Special Lecture – Lessons Learned from Cancer Precision Medicine
Todd Golub, MD, PhD

Epidemiology and Genetics
Lorelei Mucci, MD, ScD

Screening in 2024 : Role of PSA and Novel Biomarkers
Adam Kibel, MD

Advances in Multiparametric MRI for Diagnosis and Staging
Clare Tempany, Afdhal, MD, MB, BAO, BCh

Biopsy Techniques TP v. TR
Douglas M. Dahl, MD

Interpreting Prostate Biopsy Reports
Michelle Hirsch, MD, PhD

Panel - Screening and Diagnosis
Moderator: Anthony V. D’Amico, MD, PhD
Lorelei Mucci, MD, ScD; Adam Kibel, MD; Clare Tempany, Afdhal, MD, MB, BAO, BCh; Michelle Hirsch, MD, PhD; Douglas M. Dahl, MD

Break

Lessons in Quality Improvement: The MUSIC Collaborative
Brent Hollenbeck, MD

Gleason 6 PC is Not PC?: Pro
Scott Eggener, MD

Gleason 6 PC is Not PC?: Con
Derya Tilki, MD

Focal Therapy for Intermediate Risk PC
Alexander Cole, MD

How I Think About Intermediate-Risk Prostate Cancer: Surgery and Otherwise
Scott Eggener, MD

Hypofractionation and ADT Use in Intermediate Risk Prostate Cancer
Neil Martin, MD, MPH

MRI Guided Radiation Therapy
Jonathan Leeman, MD

Mgt of Non-metastatic High Risk PC: Perspectives from Urology, Radiation and Medical Oncology
Quoc-Dien Trinh, MD, FACS; Anthony V. D'Amico, MD, PhD; Praful Ravi, MD, MB, BChir, MRCP

Panel - Patient Selection
Moderator: Anthony V. D’Amico, MD, PhD
Alexander Cole, MD; Quoc-Dien Trinh, MD, FACS; Neil Martin, MD, MPH; Jonathan Leeman, MD; Praful Ravi, MD, MB, BChir, MRCP; Scott Eggener, MD; Derya Tilki, MD

Lunch

The Advanced Prostate Cancer Consensus Conference (APCCC): Today and Tomorrow
Silke Gillessen, MD

Evolving Treatment of Oligo Metastatic Disease –Integration of Surgery
Derya Tilki, MD

Evolving Treatment of Oligo Metastatic Disease – Integration of Radiation
Martin King, MD

Precision Medicine and Biomarkers in Metastatic Prostate Cancer
Himisha Beltran, MD

PSMA PET as a Diagnostic Modality
Heather Jacene, MD

Panel – Updates in Diagnostics and Special Populations
Moderator: Adam Kibel, MD
Martin King, MD; Himisha Beltran, MD; Heather Jacene, MD; Derya Tilki, MD

Break

Postoperative Management of Prostate Cancer
Anthony V. D'Amico, MD, PhD

Management of Advanced Prostate Cancer in the Elderly
Alicia Morgans, MD, MPH

Survivorship and Side Effects of ADT
Philip Saylor, MD

Management of Side Effects of Radical Prostatectomy in the Denovo and Recurrent Settings
Peter Chang, MD, MPH

Management of Side Effects of Radiation Therapy in the Denovo and Recurrent Setting
Daniel Schmidt, MD, PhD

Management of the Side Effects of non-ADT Systemic Treatment for Prostate Cancer
Mark Pomerantz, MD

Panel – Management of Treatment Related Toxicity and Recurrent Disease
Moderator: Adam Kibel, MD
Anthony V. D'Amico, MD, PhD; Alicia Morgans, MD, MPH; Peter Chang, MD, MPH; Daniel Schmidt, MD, PhD; Mark Pomerantz, MD; Philip Saylor, MD

Management of the Rising PSA in the Patient with M0 Castrate Resistant Prostate Cancer
Atish Choudhury, MD, PhD

Personalizing Treatment Selection in Metastatic, Hormone-sensitive Prostate Cancer
David Einstein, MD

Immunotherapy for Prostate Cancer
Xiao Wei, MD, MAS

Novel Androgen Receptor Targeted therapy of Castrate Resistant M1 PC
Jacob Berchuck, MD

Theranostics for Prostate Cancer: Now and Tomorrow
Praful Ravi, MD, MB, BChir, MRCP

Expert Panel: Management of Metastatic Prostate CancerMo
Moderator: Glenn Bubley, MD
Atish Choudhury, MD, PhD; Xiao Wei, MD, MAS; Praful Ravi, MD, MB, BChir, MRCP; David Einstein, MD; Jacob Berchuck, MD

Break

Role of Biomarkers in Diagnosis and Follow-up of Superficial Bladder Cancer
Adam Feldman, MD, MPH

Management of Superficial Bladder Cancer: BCG and reTURBT
Boris Gershman, MD

Management of High Grade Superficial Bladder Cancer Outside BCG: Local Therapies
Mark Preston, MD, MPH

Management of Upper Tract Disease
Matthew Mossanen, MD, MPH

Cystectomy and Diversion – Choices and Outcomes
Andrew Wagner, MD

Hereditary Syndromes in GU Cancers
Michael Serzan, MD

Genomic Predictors of Response to Systemic Therapy in Bladder Cancer
Kent Mouw, MD, PhD

Lunch

Neoadjuvant and Adjuvant Therapies
Charlene Mantia, MD

Bladder Sparing Approaches
Jason Efstathiou, MD, DPhil, FASTRO, FACRO

Management of Advanced Disease in 2024
Joaquim Bellmunt, MD, PhD

Panel - Bladder Cancer
Moderator: Adam Kibel, MD
Adam Feldman, MD, MPH; Mark Preston, MD, MPH; Matthew Mossanen, MD, MPH; Andrew Wagner, MD; Kent Mouw, MD, PhD; Jason Efstathiou, MD, DPhil, FASTRO, FACRO; Joaquim Bellmunt, MD, PhD; Boris Gershman, MD; Charlene Mantia, MD; Michael Serzan, MD

Judah Folkman Lecture: Research: Discovery, Hope and Health
Mona Hanna, MD

Break

Surgical Management of Non-seminomatous Germ Cell Tumor
Timothy Clinton, MD, MPH

Updates in Radiation Therapy in Testis Cancer
Sophia Kamran, MD

Management of Advanced Disease-Chemotherapy
Alok Tewari, MD, PhD

Emerging Role of Genomics in Testis Cancer
Eliezer Van Allen, MD

Panel - Testis Cancer
Moderator: Adam Kibel, MD
Timothy Clinton, MD, MPH; Sophia Kamran, MD; Alok Tewari, MD, PhD; Eliezer Van Allen, MD

Updates in the Pathology Classification of Renal Cell Cancer
Michelle Hirsch, MD, PhD

Role of Observation and Ablation for Small Renal Mass
Aria Olumi, MD

Radical or Partial Nephrectomy: Techniques and Innovations
Steven Chang, MD, MS

Managing the Primary when Metastatic and Metastatectomy
Keyan Salari, MD, PhD

Adjuvant Strategies in RCC
Bradley McGregor, MD

Break

Advanced Disease: First Line Options
Vincent Xu, MD

Advanced Disease: Post IO Setting
David McDermott, MD

Non Clear Cell RCC
Bradley McGregor, MD

Novel Targets Beyond Targeted Agents and IO Drugs
Xin Gao, MD

Expert Panel: Renal Cell Carcinoma
Moderator: Bradley McGregor, MD
Michelle Hirsch, MD, PhD; Aria Olumi, MD; Steven Chang, MD, MS; Keyan Salari, MD, PhD; David McDermott, MD; Xin Gao, MD; Vincent Xu, MD